文献速递神经核医学

DAT-SPECT对疑似帕金森综合征患者管理决策的影响

Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism.
PubMed 文献 · Clin Nucl Med · 2018-01-01

这项回顾性研究分析了2011至2014年间173例疑似帕金森综合征患者的DAT-SPECT扫描结果与临床管理变化。结果显示,DAT-SPECT结果影响了44.7%疑似帕金森综合征患者的治疗决策。

要点

  • DAT-SPECT结果影响了44.7%疑似帕金森综合征患者的治疗决策。
  • 正常DAT-SPECT患者中39.4%(28/54)管理发生改变,包括继续观察23.9%(17/28)。
  • 异常DAT-SPECT患者中37.3%(38/80)管理发生改变,其中89.5%(34/38)启动新PD治疗。

核心结论

  • DAT-SPECT检查结果影响了44.7%疑似帕金森综合征患者的治疗决策。

研究设计与样本

  • 本研究为经机构审查委员会批准的回顾性研究,回顾了2011至2014年间由运动障碍专科医生和神经科医生开具的DAT-SPECT扫描。
  • 共纳入173例疑似帕金森综合征患者(男性104例,女性69例;年龄64.4±12.6岁),症状中位持续时间为36个月(范围1-480个月)。

主要发现

  • 申请DAT-SPECT最常见的原因是临床特征存在诊断不确定性(59.6%,103/173),其次是鉴别其他疾病如帕金森病(PD)与特发性震颤(23.7%,41/173)、PD与药物性帕金森综合征(8.7%,15/173)、PD与心因性(6.4%,11/173)或血管性(1.7%,3/173)疾病。
  • 根据DAT-SPECT结果,异常者占59%(102/173),正常者占41%(71/173)。
  • 正常DAT-SPECT组随访管理数据可获取者占76.1%(54/71),其中39.4%(28/54)管理发生改变:4.2%(3/28)启动新的适当药物或支持治疗,11.3%(8/28)停用不适当的多巴胺能治疗,23.9%(17/28)继续观察。
  • 异常DAT-SPECT组随访管理数据可获取者占78.4%(80/102),其中37.3%(38/80)管理发生改变:89.5%(34/38)启动新的PD治疗,5.3%(2/38)调整药物剂量但原治疗未变,2.6%(1/38)停止PD治疗,2.6%(1/38)尽管DAT-SPECT异常但基于神经科医生临床决策停用PD治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the value of I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) to change management strategies of patients suspected of parkinsonism. METHOD: This was an institutional review board-approved, retrospective study. DAT-SPECT scans ordered by movement disorder specialist and neurologists from 2011-2014 were reviewed. Clinical data and radiological reports of 173 patients suspected of parkinsonism were reviewed. The DAT-SPECT scan results were correlated with clinical assessment and treatment changes. RESULTS: A total of 173 patients (104 male and 69 female subjects; age, 64.4 ± 12.6 years) suspected of parkinsonism were included. Median duration of symptoms was 36 months (range, 1-480 months). Scans were most often requested when there was diagnostic uncertainty in clinical features (59.6%, 103/173) or to differentiate one other disease from parkinsonism such as Parkinson disease (PD) versus essential tremor (23.7%, 41/173), PD versus drug-induced parkinsonism (8.7%, 15/173), or PD versus psychogenic (6.4%, 11/173) or vascular (1.7%, 3/173) disorders. Patients were classified, according to the DAT-SPECT scanning results, as those with abnormal DAT-SPECT findings (59%, 102/173) and those with normal DAT-SPECT findings (41%, 71/173). In patients with normal DAT-SPECT findings, follow-up management data were available in 76.1% (54/71). The management changed in 39.4% (28/54) after DAT scan with starting a new appropriate medications or supportive therapy in 4.2% (3/28), withholding inappropriate dopaminergic treatment in 11.3% (8/28), or continuing observation in 23.9% (17/28). In patients with abnormal DAT-SPECT findings, follow-up management data were available in 78.4% (80/102). There was change in management of 37.3% (38/80), a new PD treatment was started in 89.5% (34/38). The dose of medication was adjusted in 5.3% (2/38), although the original treatment was not changed. Parkinson disease treatment was stopped in 2.6% (1/38) and discontinued in 2.6% (1/38) based on clinical decision of neurologists despite abnormal DAT-SPECT findings. CONCLUSIONS: DAT-SPECT findings impacted treatment decisions in 44.7% of patients suspected of Parkinsonism.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mirpour S, Turkbey EB, Marashdeh W, et al. Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism. Clin Nucl Med. 2018. PMID: 30153144. doi:10.1097/RLU.0000000000002240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。